Literature DB >> 20124951

Vascular endothelial growth factor pathway.

Michael L Maitland1, Xing Jian Lou, Jacqueline Ramirez, Apurva A Desai, Dorit S Berlin, Howard L McLeod, Ralph R Weichselbaum, Mark J Ratain, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20124951      PMCID： PMC3086058          DOI： 10.1097/FPC.0b013e3283364ed7

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  22 in total

1.  Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.

Authors:  Li Sun; Chris Liang; Sheri Shirazian; Yong Zhou; Todd Miller; Jean Cui; Juri Y Fukuda; Ji-Yu Chu; Asaad Nematalla; Xueyan Wang; Hui Chen; Anand Sistla; Tony C Luu; Flora Tang; James Wei; Cho Tang
Journal:  J Med Chem       Date:  2003-03-27       Impact factor: 7.446

Review 2.  Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.

Authors:  James R Tonra; Daniel J Hicklin
Journal:  Immunol Invest       Date:  2007       Impact factor: 3.657

3.  Association of genetic polymorphisms in the VEGF gene with breast cancer survival.

Authors:  Hua Lu; Xiao-Ou Shu; Yong Cui; Nobuhiko Kataoka; Wanqing Wen; Qiuyin Cai; Zhi-Xian Ruan; Yu-Tang Gao; Wei Zheng
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

4.  AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.

Authors:  Anthony Polverino; Angela Coxon; Charlie Starnes; Zobedia Diaz; Thomas DeMelfi; Ling Wang; James Bready; Juan Estrada; Russell Cattley; Stephen Kaufman; Danlin Chen; Yongmei Gan; Gondi Kumar; James Meyer; Sesha Neervannan; Gonzalo Alva; Jane Talvenheimo; Silvia Montestruque; Andrew Tasker; Vinod Patel; Robert Radinsky; Richard Kendall
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

5.  Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.

Authors:  Simon L Goodman; Günter Hölzemann; Gábor A G Sulyok; Horst Kessler
Journal:  J Med Chem       Date:  2002-02-28       Impact factor: 7.446

6.  Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis.

Authors:  Qianren Jin; Kari Hemminki; Kerstin Enquist; Per Lenner; Ewa Grzybowska; Rüdiger Klaes; Roger Henriksson; Bowang Chen; Jolanta Pamula; Wioletta Pekala; Helena Zientek; Jadwiga Rogozinska-Szczepka; Beata Utracka-Hutka; Göran Hallmans; Asta Försti
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

7.  Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.

Authors:  Hope S Rugo; Roy S Herbst; Glenn Liu; John W Park; Merrill S Kies; Heidi M Steinfeldt; Yazdi K Pithavala; Steven D Reich; James L Freddo; George Wilding
Journal:  J Clin Oncol       Date:  2005-07-18       Impact factor: 44.544

8.  Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort.

Authors:  Eric J Jacobs; Heather Spencer Feigelson; Elizabeth B Bain; Kerri A Brady; Carmen Rodriguez; Victoria L Stevens; Alpa V Patel; Michael J Thun; Eugenia E Calle
Journal:  Breast Cancer Res       Date:  2006-04-13       Impact factor: 6.466

9.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

10.  ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Authors:  Stephen R Wedge; Donald J Ogilvie; Michael Dukes; Jane Kendrew; Rosemary Chester; Janet A Jackson; Sarah J Boffey; Paula J Valentine; Jon O Curwen; Helen L Musgrove; George A Graham; Gareth D Hughes; Andrew P Thomas; Elaine S E Stokes; Brenda Curry; Graham H P Richmond; Peter F Wadsworth; Alison L Bigley; Laurent F Hennequin
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701
View more
  9 in total

1.  PharmGKB: the Pharmacogenomics Knowledge Base.

Authors:  Caroline F Thorn; Teri E Klein; Russ B Altman
Journal:  Methods Mol Biol       Date:  2013

2.  Genome-Wide Association Study Reveals Multiple Novel QTL Associated with Low Oxygen Tolerance in Hybrid Catfish.

Authors:  Xiaoxiao Zhong; Xiaozhu Wang; Tao Zhou; Yulin Jin; Suxu Tan; Chen Jiang; Xin Geng; Ning Li; Huitong Shi; Qifan Zeng; Yujia Yang; Zihao Yuan; Lisui Bao; Shikai Liu; Changxu Tian; Eric Peatman; Qi Li; Zhanjiang Liu
Journal:  Mar Biotechnol (NY)       Date:  2017-06-10       Impact factor: 3.619

Review 3.  PharmGKB summary: pazopanib pathway, pharmacokinetics.

Authors:  Caroline F Thorn; Manish R Sharma; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-08       Impact factor: 2.089

4.  Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathway.

Authors:  Laia Paré-Brunet; Dylan Glubb; Patrick Evans; Antoni Berenguer-Llergo; Amy S Etheridge; Andrew D Skol; Anna Di Rienzo; Shiwei Duan; Eric R Gamazon; Federico Innocenti
Journal:  Hum Mutat       Date:  2013-11-27       Impact factor: 4.878

5.  Genome-wide association analysis of adaptation to oxygen stress in Nile tilapia (Oreochromis niloticus).

Authors:  Xiaofei Yu; Hendrik-Jan Megens; Samuel Bekele Mengistu; John W M Bastiaansen; Han A Mulder; John A H Benzie; Martien A M Groenen; Hans Komen
Journal:  BMC Genomics       Date:  2021-06-09       Impact factor: 3.969

6.  Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?

Authors:  Muhammad Wasif Saif
Journal:  Cancer Manag Res       Date:  2013-06-11       Impact factor: 3.989

7.  Genomic landscape of metastatic colorectal cancer.

Authors:  Josien C Haan; Mariette Labots; Christian Rausch; Miriam Koopman; Jolien Tol; Leonie J M Mekenkamp; Mark A van de Wiel; Danielle Israeli; Hendrik F van Essen; Nicole C T van Grieken; Quirinus J M Voorham; Linda J W Bosch; Xueping Qu; Omar Kabbarah; Henk M W Verheul; Iris D Nagtegaal; Cornelis J A Punt; Bauke Ylstra; Gerrit A Meijer
Journal:  Nat Commun       Date:  2014-11-14       Impact factor: 14.919

Review 8.  Pharmacogenetic-Based Interactions between Nutraceuticals and Angiogenesis Inhibitors.

Authors:  Raffaele Di Francia; Massimiliano Berretta; Giulio Benincasa; Alfredo D'Avino; Sergio Facchini; Domenico Costagliola; Paola Rossi
Journal:  Cells       Date:  2019-05-30       Impact factor: 6.600

9.  Multiple delivery of siRNA against endoglin into murine mammary adenocarcinoma prevents angiogenesis and delays tumor growth.

Authors:  Tanja Dolinsek; Bostjan Markelc; Gregor Sersa; Andrej Coer; Monika Stimac; Jaka Lavrencak; Andreja Brozic; Simona Kranjc; Maja Cemazar
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.